Good evening to All.

Thank You very much for providing Mr. Anbaz’s (name changed) report. He was diagnosed in 2019 with Glioblastoma Multiforme, he completed treatment protocol and was off chemo for 1 year when he developed recurrence.

Now we did NGS from our Canary Oncoceuticals and believe me, I am overjoyed to see this report. He has IDH R132H mutation where in Arginine replaces Histidine at position 132 which confers a very good Progression free survival and Overall survival (The OS of GBM is only 12 ton18 months)

He also has a CCND2 Mutation for which we can try Abemaciclib at the time of recurrence.

Also his TMB is high for which I had initially planned NIVOLUMAB ( Immunotherapy) provides i get this report and I have!

Much appreciated Dear Harry Sir and Team

Hi Dr. Harry,

I read Mrs. Lakashmi’s (name changed) report. It's profoundly impressive wherein her study on the breast biopsy has revealed - MLH1, HER2 , MSH3 and a high TMB. Practical enough to follow Immunotherapy as maintenance after she completes her chemotherapy sessions. Regarding the ovarian biopsy, mutation in TP53, is likely a somatic. What is impressive, that she comes under the umbrella of Lynch syndrome.

I am really impressed with the reporting and efficacy it has demanded.

He also has a CCND2 Mutation for which we can try Abemaciclib at the time of recurrence.

Thank you.

Hi Dr Harry,

Thank you very much, here is my feedback on two of my patients who has undergone NGS testing at Canary. (1). 58 year male with lung adenocarcinoma. Initial NGS testing went to a local Indian company with negative results. We sent the same sample to Canary and interestingly a RET-CCDC6 fusion with actionable therapies was detected. The patient was given the recommended targeted therapy and is responding very well. Thank you for such a valuable clinical report.

(2). 52 year female with breast cancer experienced a cardiac event under chemo. The sample was sent for NGS at Canary and a MAP2K2 mutation was detected. I wish I knew she had a MAP2K2 mutation before I had started chemo. As we know MAP2K2 mutations are associated with chemo-induced cardiac events.

Thank you.